	A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets. bioRxiv Perny A, Jarmale V, Jasti J, Zhong H, Christie A, Miyata J, Nielson A, Kontoyiannis P, Rakheja D, Modrusan Z, Huseni M, Kadel W, Brugarolas J, Kapur P, Rajaram S. PMID: 42395467 [PubMed - in process]
	Optimization of Administered Activity for (64) Cu-SAR-bisPSMA PET Imaging in Primary Prostate Cancer: Results from a Phase I Retrospective Study (PROPELLER Sub-study). World J Nucl Med Lengyelova E, Patel M, Morrish G, Mittra E, Malaroda A, Gervasio O, Armor T. PMID: 42395167 [PubMed]
	LLMs in Problem-Based Learning: The Grounding Issue. Stud Health Technol Inform Sariyar M. PMID: 42394097 [PubMed - indexed for MEDLINE]
	Estimating Mosaic Loss of the Y Chromosome in Male Bladder Cancer Participants Using "All of Us" Data. Stud Health Technol Inform Ye Z, Cui W, Theodorescu D, Finkelstein J. PMID: 42394043 [PubMed - indexed for MEDLINE]
	When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [Â¹â¸F]FDG in high-risk prostate cancer: dual-tracer cohort study. Cancer Imaging Ibrahim EA, Alper E. PMID: 42393801 [PubMed - as supplied by publisher]
	Quality of services and patient reported outcomes for prostate cancer in Tanzania: the role of patients' satisfaction from a cross-sectional study. BMC Urol Nyongole O, Munishi C, Kimu N, Shirima GV, Sangeda RZ, Mseti M, Lugina E, Kiwara F, Sirili N, Chacha F, Nicholaus B, Mruma H, Frumence G, Simba D, Urassa D, Sunguya B. PMID: 42393670 [PubMed - as supplied by publisher]
	Gamma knife radiosurgery for renal cell carcinoma brain metastases across systemic therapy eras: survival, intracranial failure, and lesion-level predictors. J Neurooncol Almeida ND, Sinha S, Fang M, Cheruvu H, Tasgaonkar R, Gulzar B, Madhugiri V, Goulenko V, Prasad D. PMID: 42393321 [PubMed - indexed for MEDLINE]
	Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study. NPJ Precis Oncol Rebuzzi SE, Miskovic V, Fornarini G, Ferri S, Buti S, Piceni M, Signori A, Provenzano L, Banna GL, Rescigno P, Maruzzo M, Bimbatti D, Pollone BR, Basso U, De Giorgi U, Pedrazzoli P, Galli L, Zucali PA, Di Costanzo F, Ghose A, Pedrocchi ALG, Prelaj A. PMID: 42393181 [PubMed - as supplied by publisher]
	Should Male Pattern Baldness Be Considered in Prostate Cancer Risk Assessment? A Systematic Review and Meta-analysis. Eur Urol Focus Larose C, Samhani C, Piché ME, Lachance G, Fradet Y, Robitaille K, Fradet V. PMID: 42392953 [PubMed - as supplied by publisher]
	Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely. Eur Urol Contieri R, van der Heijden AG, Mertens LS. PMID: 42392908 [PubMed - as supplied by publisher]
	Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined (18)F-Flotufolastat PSMA PET and mpMRI. J Nucl Med Hekimsoy T, Sauter AP, Tauber R, Horn T, Jahnen M, Horné F, Petzold JQ, Sasse D, Rauscher I, Eiber M, Weber WA, Erber BM. PMID: 42392697 [PubMed - as supplied by publisher]
	Sensitive detection of prostate cancer antigen 3 (PCA3) in urine based upon CRISPR/Cas12a and gold nanorods (AuNRs). Spectrochim Acta A Mol Biomol Spectrosc Liao W, Li S, Wu S, Yang X, Liu B, Ling L, Zeng Q, Zhang J. PMID: 42391902 [PubMed - as supplied by publisher]
	Assessing the impact of prostate cancer prevention and detection initiatives. Int J Palliat Nurs Narvaez RA, Bongay R, Federez IC, Chan EB, Magno D, Samarita JC, Ferrer M, Peco RA, Sumpay LA, Sangilan NB. PMID: 42391137 [PubMed - indexed for MEDLINE]
	Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer. Clin Cancer Res Lotan Y, Luu M, Liu M, Tikhonekov S, Kobayashi T, Ahdoot M, Kim HL, Porten S, Peers G, Kita Y, Daskivich T, Murakami K, Sakatani T, Pagano I, Zheng Y, Zhang Z, Furuya H, Rosser CJ. PMID: 42391037 [PubMed - as supplied by publisher]
	Comprehensive Approach to Prostate Cancer Metastasis Mimics at Prostate-Specific Membrane Antigen PET/CT. Radiographics Rafiei Alavi N, Gupta A, Rahmani M, Alexander S, Afsari A, Jafarvand Giglou M, Srinivas SM, Yaghmai V. PMID: 42391030 [PubMed - indexed for MEDLINE]
	Safety and efficacy of different surgical approaches in single-port robot-assisted radical prostatectomy based on propensity score matching analysis. World J Urol Qi JC, Liu L, Tang S, Yang HX, Santodirocco L, Xia YR, Morgantini LA, Sauer Calvo R, Qu CB, Wang YX, Crivellaro S. PMID: 42390762 [PubMed - indexed for MEDLINE]
	HER2 assessment in urothelial carcinoma: standardization challenges and the path forward. Cancer Metastasis Rev Xie P, Wang Y, Lu L, Chen J, Wei J, Huang Y, Guo C, Li J, Yan X, Guo J, Wu X, Sheng X. PMID: 42390654 [PubMed - indexed for MEDLINE]
	Transurethral Ropivacaine (100 mg) Bladder Irrigation Reduces the Incidence of Bladder Discomfort in Transurethral Resection of Bladder Tumor: A Randomized Double-blind Trial. Ann Afr Med Ranjan R, Singh AK, Sachan S, Singh Y, Gupta R, Nayak AK, Kumar R, Bhargavan A. PMID: 42390337 [PubMed - as supplied by publisher]
	Ablative radiotherapy in castration-resistant prostate cancer. BJU Int Hölscher T, Lohaus F, Koi L, Kotzerke J, Hoberück S, Thomas C, Borkowetz A, Löck S, Krause M, Troost EGC. PMID: 42389925 [PubMed - as supplied by publisher]
	Venous thromboembolism after penile cancer surgery: a UK PeCaN study. BJU Int Kaur A, El-Taji O, Alnajjar H, Ayres B, Christodoulidou M, Eardley I, Elmamoun M, Goddard J, Gordon P, Hadway P, Kalejaiye O, Keegan P, Kumar V, Lau M, Manjunath A, McGuinness L, Mulholland C, Muneer A, Panagiotis C, Randhawa K, Sahdev V, Shukla C, Watkin N, Sachdeva A, Parnham A, Sangar V. PMID: 42389899 [PubMed - as supplied by publisher]

Articles 1 - 20 / 179718

Page 1 of 8986



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy